Dr. Dharma Ram Poonia 🇮🇳

Find me here @IASO_IJSOonline As section Editor of Head and Neck Oncology #OralCancer #HNC #oralCancer #IASO #Cancer #SurgicalOncology link.springer.com/journal/13193/…

🚨 New ASCO Guidelines (2026): Well-Differentiated Thyroid Cancer This is a major shift in how we treat RAI-refractory disease 👇 🧠 Step 1 is no longer MKI… it’s GENOMICS 👉 Test for: RET | NTRK | BRAF If actionable → Targeted therapy FIRST • RET → Selpercatinib (LIBRETTO-001) • NTRK → Larotrectinib (pooled TRK trials) / Entrectinib (STARTRK) • BRAF → Dabrafenib ± Trametinib (phase II BRAF studies) 🔥 Deep, durable responses > MKIs 📊 Signal strength • NTRK inhibitors → ORR ~57–86% • RET inhibitors → ORR ~79–90% 🧠 If no mutation (or not feasible) 👉 First-line MKI • Lenvatinib (SELECT) • Sorafenib (DECISION) 📊 SELECT → PFS 18.3 vs 3.6 mo DECISION → PFS 10.8 vs 5.8 mo 👉 Lenvatinib preferred (higher ORR, longer PFS) 🧠 After progression 👉 Cabozantinib (COSMIC-311) 📊 PFS 11.0 vs 1.9 mo 🧠 Immunotherapy? ❌ Not upfront 👉 Consider only post-progression Lenvatinib + Pembrolizumab (KEYNOTE-158 / ITOG study) 🧠 Chemotherapy 👉 Last-line only 🎯 Practice-changing shift Old → Start MKI for all New → Test → Target → Then MKI → Then Cabo 💡 Thyroid cancer is now a precision oncology disease 🔖 Save this before your next thyroid clinic #OncoTwitter #MedTwitter #ThyroidCancer #PrecisionOncology @OncoAlert @myesmo @esmo_open @asco

Indeed a extraordinary work. Kudos @aiims_jodhpur Dr. Mohit Agrawal Dr. Bhaskar Dr. Samhita Panda Dr. Lokesh Saini Dr. Manbir Dr. Bhatia.

Join us LIVE from AIIMS Jodhpur! Witness the Inaugural Session for the January 2026 Postgraduate Batch with eminent guests Dr. D. Nageshwar Reddy, Prof. (Dr.) Tejas M. Patel & Prof. Avinash Kumar Agarwal. 📺 Watch here: youtube.com/live/1xdfP7KIH…

A nice opportunity

@DrRishabhOnco Nice illustration..

🧬 New triplet strategy in gastric cancer Targeting CLDN18.2 + PD-1 + chemotherapy may significantly deepen responses in metastatic gastric/GEJ cancer. A phase II ILUSTRO cohort tested: 🧪 Zolbetuximab + Nivolumab + mFOLFOX6 in 1L HER2-negative CLDN18.2-positive gastric/GEJ adenocarcinoma. 📊 Key results • Median PFS: 14.8 months • CLDN18.2-high tumors: PFS 18.0 months • ORR: 62% • Disease control: ~90% 🔬 Biology makes sense Zolbetuximab → tumor cell killing via CLDN18.2 ↓ Antigen release + immune priming ↓ PD-1 blockade amplifies T-cell response 🎯 Best outcomes seen when BOTH biomarkers present CLDN18.2-high + PD-L1 CPS ≥1 → PFS 23.6 months ⚠️ Toxicities consistent with regimen Main AEs: nausea, appetite loss, neutropenia. 🚨 Why this matters Gastric cancer may be moving toward dual biomarker-guided triplet therapy rather than chemo-IO alone. Phase III LUCERNA trial will decide if this becomes a new standard. #OncoTwitter #MedTwitter #GastricCancer #PrecisionOncology @OncoAlert @myESMO @ASCO

On National Immunization Day, vaccines are powerful tools in preventing certain cancers. Hepatitis B and HPV vaccines play a vital role in preventing liver and cervical cancers, highlighting the importance of immunization in cancer prevention. #NationalImmunizationDay

@aiims_jodhpur Congratulations.

घुटने के लिगामेंट (ACL) उपचार में एम्स जोधपुर की बड़ी उपलब्धि! डॉ. नितेश गहलोत के शोध से मजबूत ग्राफ्ट विकल्प और बेहतर रिकवरी के नए रास्ते सामने आए हैं, इससे सर्जरी के बेहतर परिणाम, ताकत में सुधार और दोबारा चोट का खतरा कम हो सकता है। अब मरीज अधिक सुरक्षित और बेहतर तरीके से सामान्य जीवन में लौट सकते हैं। #AIIMSJodhpur #ACLInjury #SportsInjury #Healthcare @JPNadda @mpprataprao @AnupriyaSPatel @MoHFW_INDIA

A touching tribute at AIIMS Jodhpur to our silent heroes—the organ donors @aiims_jodhpur #GIftOfLife

#HappyHoli Let this Holi bring loads of Joy and wellness.

Hpv Vaccination Campaign Rajasthan: PM to launch HPV vaccination drive in Ajmer | Jaipur News - The Times of India share.google/TKH3845sJVLyGE… Historical move

Indeed a nice initiative.

Such a brilliant move. Dedicated to young ones. @aiims_jodhpur @aiims_newdelhi @AIIMSBhubaneswr @AiimsBathinda @AiimsJammu @aiimsrishi @AIIMSBhopal @AiimsKalyani @AIIMS_bilaspur @AIIMSNagpur

@drsabita @DOTEsophagus @ISDE_net @MagnusNsurgonc @esophaguideMD For all Adeno, #FLOT is favorite, until have access to MATTERHORN with ease.

The #ESOPEC trial reignited the debate in resectable #esophageal adenocarcinoma. #FLOT vs #CROSS. 66 vs 37 months median OS. Practice-changing? Or a result that needs careful interpretation? Four editorials in @DOTEsophagus explore the implications.

@IASO_IJSOonline @somusp9 @DrPankajGarg @drraulinsa @oncodaily @official_IASO @IASOmasterclass @harit_oncochat @cspramesh @basavatarakam

#IJSOVA #IASOIJSOinitiative #Medtwitter #Esophagealcancer #Cancersurgery Post Esophagectomy Anastomotic leaks ?? Switch to ICG angiography. check out this metanalysis, recently published in IJSO . doi.org/10.1007/s13193…

ICG reduced odds of AL by 58% (9% vs. 15.5%; OR 0.42, 95% CI: 0.26–0.70; I²=42%), with an absolute risk difference of 6.5% (95% CI: 3.3–9.7) and a number needed to treat (NNT) of 15 (10–30) @ISDE_net @IASO_IJSOonline @aiims_jodhpur @aiims_newdelhi #LandMark Meta-analysis

@aiims_newdelhi Congratulations. Well deserving without a doubt.

AIIMS Delhi has been named the 6th best hospital globally in the 2026 Brand Finance rankings. Standing alongside institutions like Johns Hopkins and Oxford, we remain steadfast in our mission to provide excellence in care, research, and teaching. visualcapitalist.com/dp/the-worlds-…

@aiims_jodhpur It is indeed, kudos.

AIIMS Jodhpur Gynecology Dept successfully removed a rare giant retroperitoneal aggressive angiomyxoma (21×10.5×7.5 cm) using a minimally invasive laparoscopic & perineal approach - the largest laparoscopic removal in Rajasthan. A triumph of meticulous planning & teamwork. #AIIMSJodhpur #GyneSurgery #RetroperitonealTumor #MinimallyInvasiveSurgery @JPNadda @mpprataprao @AnupriyaSPatel @MoHFW_INDIA

@aiims_newdelhi @MoHFW_INDIA @CSIR_IND @DBTIndia @IndiaDST @iitdelhi @ICMRDELHI @ANRFIndia Interesting to know the detials. Hopefully something on MOUs and IEC related point with networking platform to ease the collaboration.

A defining moment for Indian medical research! Leaders from all AIIMS institutions come together to formalise the Pan-AlIMS Research Consortium, strengthening collaboration to advance health research and impact. 29.01.2026 🔬 #PanAlIMSResearchConsortium #AIIMSResearchDay

Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial - The Lancet thelancet.com/journals/lance…

Article worth a notice nejm.org/doi/full/10.10…